Overview

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes Inadequately Controlled With Diet and Exercise Alone

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effectiveness of HRS9531 compared to placebo in controlling blood glucose levels after 24 weeks of treatment
Phase:
PHASE3
Details
Lead Sponsor:
Fujian Shengdi Pharmaceutical Co., Ltd.